Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $251.1 million.

  • Roivant Sciences' Total Liabilities fell 204.04% to $251.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $251.1 million, marking a year-over-year decrease of 204.04%. This contributed to the annual value of $249.7 million for FY2025, which is 6773.16% down from last year.
  • According to the latest figures from Q4 2025, Roivant Sciences' Total Liabilities is $251.1 million, which was down 204.04% from $257.1 million recorded in Q3 2025.
  • In the past 5 years, Roivant Sciences' Total Liabilities registered a high of $822.5 million during Q2 2022, and its lowest value of $216.7 million during Q2 2025.
  • Its 5-year average for Total Liabilities is $564.6 million, with a median of $613.6 million in 2024.
  • Per our database at Business Quant, Roivant Sciences' Total Liabilities surged by 7321.05% in 2022 and then tumbled by 6773.16% in 2025.
  • Quarter analysis of 5 years shows Roivant Sciences' Total Liabilities stood at $529.6 million in 2021, then soared by 46.49% to $775.8 million in 2022, then dropped by 6.15% to $728.1 million in 2023, then tumbled by 64.79% to $256.4 million in 2024, then decreased by 2.04% to $251.1 million in 2025.
  • Its Total Liabilities was $251.1 million in Q4 2025, compared to $257.1 million in Q3 2025 and $216.7 million in Q2 2025.